Table 4.
Tumor-associated inflammation in metastatic cancer
| Trial | Frequency of CRP elevation >10 mg/L (%) | CRP >30% response (% patients) | Significance of CRP response during 2 to 6 weeks on treatment | Improvement of ECOG status % patients | Progression-free survival and overall survival |
|---|---|---|---|---|---|
| RenaI clear cell carcinoma I | 72 | 69 | p = 0.32 | 22 | Significant improvement of PFS and OS in RCCC II (non randomized) |
| Renal clear cell carcinoma II | 100 | 100 | p = 0.0005 | 24 | |
| Hormone-refractory prostate cancer* | 28 | 11 | p = 0.67 | 30 | |
| Melanoma I | 81 | 88 | p = 0.004 | 19 | |
| Melanoma II | |||||
| Arm A | 87 | 6 | p = 0.52 | 0 | Significant improvement of overall survival (CRP responder) |
| Arm B (randomized) | 100 | 69 | p = 0.0007 | 27 | |
| Sarcoma | 79 | 74 | p = 0.006 | 28 | |
| Angiosarcoma * | 100 | 100 | – | – | |
| Langerhans’ cell histiocytosis | 100 | 100 | – | 100 |
*Resolution of paraneoplastic syndromes: lupus erythematodes, hypoglycaemia